Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Amgen Starts Phase III Enrollment For Heart Failure Drug

Published 02/22/2019, 04:53 AM
Updated 07/09/2023, 06:31 AM

Amgen (NASDAQ:AMGN) , Cytokinetics, Inc. (NASDAQ:CYTK) and Servier announced that the enrollment for the second phase III study of omecamtiv mecarbil, a novel cardiac myosin activator, has been initiated. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF).

The phase III study, METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure) will evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing (CPET) in patients with HFrEF. The study is being conducted by Cytokinetics in collaboration with Amgen, with funding and strategic support from Servier.

Shares of Amgen have dropped 4.9% compared with the industry’s decline of 14.5%.

Amgen has several interesting candidates in its pipeline, which represents a significant commercial potential. The company is focusing on therapeutic areas like oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

Important pipeline candidates include Evenity/romosozumab being evaluated for the treatment of osteoporosis in postmenopausal women at increased risk for fracture and is under review in EU and United States; CNP520 is a BACE inhibitor for Alzheimer's disease and is in phase III study; and tezepelumab being developed for the treatment of severe asthma and is in phase III. Tezepelumab is also in a phase IIa study, being developed for atopic dermatitis.

Zacks Rank and Stocks to Consider

Amgen currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks are Celgene Corp. (NASDAQ:CELG) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) . Both the stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Celgene’s earnings per share estimates have increased from $10.21 to $10.69 for 2019 and from $11.63 to $12.62 for 2020 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 2.65%.

BioDelivery Sciences’ loss per share estimates have narrowed from 25 cents to 22 cents for 2019 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average of 8.57%.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



Celgene Corporation (CELG): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Cytokinetics, Incorporated (CYTK): Free Stock Analysis Report

BioDelivery Sciences International, Inc. (BDSI): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.